I found consistent changes in haematological profile of T2D patients, that can be used as clinical biomarkers including: increased count numbers of white blood cells (WBC) and platelets; decreased count numbers of red blood cells (RBC) and decreased levels of haemoglobins.
> A high WBC and platelet count predicts increased inflammation and the development of T2D.
> A low RBC count impaires iron absorption and oxygen transport, which is linked to complications in diabetic patients.
Any more consistent alterations observed in clinical reports???
Dear Thien,
To the best of my knowledge, there is no consistent hematological biomarker for type 2 diabetes (T2D). Anemia is common in such patients, but that does not make rbc counts a biomarker for T2D. Many other pathological conditions can cause anemia. Furthermore, the hematological parameters listed are patient-specific, and their circulating plasma levels may be influenced by environmental factors, socio-economic status, geographical location, and race. The only clinically relevant biomarkers for T2D are blood glucose levels and HBA1c.